Invesco Ltd. Has $1.07 Million Position in Recursion Pharmaceuticals, Inc. $RXRX

Invesco Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 13.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 202,531 shares of the company’s stock after acquiring an additional 23,912 shares during the quarter. Invesco Ltd. owned about 0.05% of Recursion Pharmaceuticals worth $1,071,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the period. GF Fund Management CO. LTD. bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $54,000. San Luis Wealth Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth about $54,000. ADG Wealth Management Group LLC bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $57,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $4.66 on Wednesday. The business has a 50 day moving average of $5.43 and a 200-day moving average of $5.58. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm has a market cap of $2.02 billion, a PE ratio of -2.62 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.40) earnings per share. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Najat Khan sold 36,599 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares in the company, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.43% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.